Drugs / YH35324
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05960708 | Aug 2023 → Sep 2024 | allergic disease, chronic idiopathic urticaria, chronic inducible urticaria, cold urticaria | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05564221 | Nov 2022 → Nov 2024 | atopic IgE-mediated allergic disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05061524 | Sep 2021 → Jan 2023 | atopic IgE-mediated allergic disorder | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH35324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05061524 ↗ |
| Action | Inhibit | “it prevents serum IgE from binding to receptors on mast cells and basophil, thereby inhibiting histamine release caused by degranulation” NCT05061524 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of YH35324” NCT05061524 ↗ |